Cell therapy (CAR-T) · Kills target cells, directed at C-type lectin-like molecule-1 (CLL-1) (CLEC12A) · developed by Caribou Biosciences
CB-012 is an allogeneic, CRISPR-edited off-the-shelf T-cell therapy carrying a chimeric antigen receptor that binds CLL-1 on tumor cells, leading to cytotoxic T-lymphocyte-mediated killing. The cells also have PD-1 knocked out and TRAC deleted to prevent graft-versus-host disease. It is studied in acute myeloid leukemia that is relapsed or refractory.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06128044 | Phase 1 | Acute Myeloid Leukemia, in Relapse | Terminated | CRBU |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRBU page.
See CRBU's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRBU catalysts and pipeline →